Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Variants in inflammatory, sex hormone metabolism, and growth factor genes and the association with benign prostatic hyperplasia

Principal Investigator
Name
Sarah Daughterty
Institution
NCI, DCEG, OEEB
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2007-0011
Initial CDAS Request Approval
Feb 26, 2007
Title
Variants in inflammatory, sex hormone metabolism, and growth factor genes and the association with benign prostatic hyperplasia
Summary
Benign prostatic hyperplasia (BPH), caused by an imbalance between cellular proliferation and death, is a very common problem among aging men (1). BPH is considered a syndrome by many clinicians with a constellation of symptoms that often include lower urinary tract symptoms, benign prostatic enlargement, and bladder outlet obstruction (2). Inflammatory causes, sex hormones, and growth factors may contribute to the growth or proliferation of the prostate. Due to the limited and somewhat conflicting associations reported on polymorphisms in cytokine, sex hormone metabolizing, and growth factor genes in relation to BPH, we propose to investigate susceptibility of BPH using existing genotype resources and questionnaire data already obtained within the screening arm of the PLCO Trial.
Aims

1) To assess the association between polymorphisms in inflammatory genes and risk of physician-diagnosed benign prostate hyperplasia or transurethral resection of the prostate (TURP).
2) To assess the association between polymorphisms in sex hormone metabolizing and growth factor genes and risk of physician-diagnosed benign prostate hyperplasia or TURP.

Collaborators

Elizabeth Platz (Johns Hopkins Bloomberg School of Public Health)
Richard Hayes (DCEG)
Wen-Yi Huang (DCEG)